Abstract
This study aimed to develop and validate an efficient and robust analytical HPLC method for the resolution and quantification of asciminib and its genotoxic impurities along with isolation and characterization of stress degradation products (DPs). Various method optimization studies were performed for development of analytical method for the analysis of asciminib and its genotoxic impurities. The DPs were characterized through LC-MS/MS and NMR spectroscopy. Further, an in-silico software assisted tools were utilized for the assessment pharmacokinetic and toxicological profile of DPs. The optimization proved Kinetex C18 (250 mm × 4.6 mm, 5 μm) column was ideal for the resolution of analytes with 0.7 mL/min flow of 0.01% formic acid buffer (pH 3.9) and acetonitrile and 276 nm wavelength. The forced degradation studies show significant degradation occurred under acidic (12.36%), basic (3.54%), oxidative (10.63%), and UV (7.28%) stress. This stress study leads to the formation of 5 DPs in acid, one DP in base, three DPs in peroxide, one DP in UV light stress study. The formed DPs were isolated through preparative HPLC and structural elucidation of DPs was conducted using LC-MS/MS and NMR spectroscopy. The toxicity and ADME profiles of the identified DPs reveal that some DPs exhibit potential hepatotoxicity, nephrotoxicity, and neurotoxicity with significant variations in toxicological and pharmacokinetic properties. The results underscore the importance of understanding the stability, toxicity, and pharmacokinetics of asciminib and its DPs for regulatory and pharmaceutical applications.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Amgoth, K. M. & Tummala, S. R. LC-MS/MS approach for the quantification of five genotoxic nitroso impurities in Varenicline. J. Pharm. Res. 26, 1685–1693. https://doi.org/10.29228/jrp.259 (2022).
Varma, B. H. R. & Rao, B. S. Gas chromatography-head space-mass spectrometry sensor based quality control of Dobutamine Hydrochloride bulk material for a mutagenic impurity, 2-bromopropane. Res. J. Chem. Environ. 27, 54–61. https://doi.org/10.25303/2702rjce054061 (2023).
Raju, P. M., Shyamala, P., Narayana, B. V., Dantuluri, H. S. & Bhupatiraju, R. V. A fast, validated UPLC method coupled with PDA-QDa detectors for impurity profiling in Betamethasone acetate and Betamethasone phosphate injectable suspension and isolation, identification, characterization of two thermal impurities. Ann. Pharm. Fr. 80, 837–852. https://doi.org/10.1016/j.pharma.2022.03.003 (2022).
Tummala, S. R. & Amgoth, K. P. Development of GC-MS/MS method for simultaneous estimation of four nitrosoamine genotoxic impurities in Valsartan. Turk. J. Pharm. Sci.19, 455–461. https://doi.org/10.4274/tjps.galenos.2021.17702 (2022).
Bhupatiraju, R. V., Rao, B. S., Venkata Narayana Rao, K. M. & Reddy, M. V. A novel Rivaroxaban degradation impurity detection by RP-HPLC extraction by preparative chromatography, and characterization by LC-MS, NMR and FT-IR: Analysis of novel impurity in batch samples and tablets of Rivaroxaban. Rasayan. J. Chem.15, 2373–2381. https://doi.org/10.31788/RJC.2022.1547008 (2022).
Bhupatiraju, R. V., Kasimala, B. B., Nagamalla, L. & Sayed, F. Structural evaluation of degradation products of Loteprednol using LC-MS/MS: Development of an HPLC method for analyzing process-related impurities of Loteprednol. Anal. Sci. Technol.37, 98–113. https://doi.org/10.5806/AST.2024.37.2.98 (2024).
Tummala, S. R., Gorrepati, N. & Tatapudi, H. K. Head space GC-MS/MS method for quantification of five nitrosoamine-genotoxic impurities in Metformin HCl. Curr. Pharm. Anal.20, 944–952. https://doi.org/10.2174/0115734129332940240919113159 (2024).
Abdel-Moety, E. M., Elragehy, N. A., Hassan, N. Y. & Rezk, M. R. Selective determination of ertapenem and imipenem in the presence of their degradants. J. Chromatogr. Sci. 48, 624–630. https://doi.org/10.1093/chromsci/48.8.624 (2010).
Rezk, M. R., Fayed, A. S., Marzouk, H. M. & Abbas, S. S. Chromatographic determination of Cyclopentolate Hydrochloride and Phenylephrine Hydrochloride in the presence of their potential degradation products. J. AOAC Int. 100, 434–444. https://doi.org/10.5740/jaoacint (2017).
Elkholy, H. A., Rezk, M. R., Abbas, S. S. & Hassan, L. A. Orthogonal biosimilarity testing of etanercept: A green and white analytical approach. Talanta 298, 128915. https://doi.org/10.1016/j.talanta.2025.128915 (2026).
Horyn, M. et al. QbD-driven RP-HPLC method for the simultaneous analysis of dihydropyridines calcium channel blockers in pharmaceuticals. BMC Chem. 19, 289. https://doi.org/10.1186/s13065-025-01661-5 (2025).
Rezk, M. R., Michael, S., Shawky, H., Badr, K. A. & Wadie, M. A novel ultra-sensitive LC-MS/MS method for determination of elobixibat in human plasma; application to a bioequivalence study on healthy volunteers. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1257, 124576. https://doi.org/10.1016/j.jchromb.2025.124576 (2025).
Mamdouh Rezk, R., Safa’a Riad, M., Fatma Khattab, I. & Marzouk, H. Multi-residues determination of antimicrobials in fish tissues by HPLC-ESI-MS/MS method. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 978, 103–110. https://doi.org/10.1016/j.jchromb.2014.12.002 (2015).
Rezk, M. R. & Badr, K. A. Development, optimization and validation of a highly sensitive UPLC-ESI-MS/MS method for simultaneous quantification of amlodipine, benazeprile and benazeprilat in human plasma: Application to a bioequivalence study. J. Pharm. Biomed. Anal. 98, 1–8. https://doi.org/10.1016/j.jpba.2014.05.005 (2014).
Breccia, M., ColaFigureli, G., Scalzulli, E. & Martelli, M. Asciminib: An investigational agent for the treatment of chronic myeloid leukemia. Expert Opin. Investig. Drugs 30(8), 803–811. https://doi.org/10.1080/13543784.2021.1941863 (2021).
Laganà, A., Scalzulli, E., Carmosino, I., Martelli, M. & Breccia, M. Asciminib as a third line option in chronic myeloid leukemia. Int. J. Hematol. 17, 16–23. https://doi.org/10.1007/s12185-022-03432-7 (2023).
Hughes, T. P. et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N. Engl. J. Med. 381, 2315–2326. https://doi.org/10.1056/nejmoa1902328 (2019).
Ogale Shital, A., Madhav Shetkar, A. & Patil, S. S. Method development and validation of Asciminib by RP-HPLC. Int. J. Pharm. Sci. 2, 278–286. https://doi.org/10.5281/zenodo.11486334 (2024).
Pridhvi Krishna, G. & Raja, S. A novel method development and validation by ultra-performance liquid chromatography for assay of Asciminib in dosage form. J. Turk. Chem. Soc. Chem. 10, 529–540. https://doi.org/10.18596/jotcsa.1228364 (2023).
Dandamudi Priya, S., Shivakumar, G. & Vasanthi, R. A novel stability indicating reversed phase ultra-performance liquid chromatography method for estimation of Asciminib its bulk and tablet formulation. I J. P Q. A 13, 490–495. https://doi.org/10.25258/ijpqa.13.4.23 (2022).
Pallavi, S. & Sowjanya, G. Quantification of Asciminib and its impurities: A RP-UPLC study. Res. J. Pharm. Technol. 17, 3430–3436. https://doi.org/10.52711/0974-360X.2024.00537 (2024).
Vijaya Lakshmi, M., Suneetha, A., Varshita, P. & Mokkapati, C. Bio-analytical method development and validation of Asciminib. N.M.R.J. 9, 181–200 (2024).
Sandhya, P., Sri Nataraj, K. & Vijayalakshmi, R. Bio-analytical method development and validation of Asciminib and its application to pharmacokinetic studies in rat plasma by using RP-HPLC. Asian J. Chem. 35, 1651–1658. https://doi.org/10.14233/ajchem.2023.27925 (2023).
Govindarao, Y. & Kumar, G. Drug development and validation of a sensitive bio-analytical LC-MS/MS method for quantification of Asciminib-a chronic myeloid leukemia drug in human plasma. J. Drug Alcohol Res. 12, 1–7. https://doi.org/10.4303/JDAR/236242 (2023).
Anusha, M. & Gubbiyappa, K. S. Bioanalytical method development and validation for the determination of Asciminib anticancer drug in biological matrices by LC–ESI-MS/MS. Int. J. Appl. Pharm. 16, 176–181. https://doi.org/10.22159/ijap.2024vv16i6.52154 (2024v).
Hema., Naresh, P. Quantification of asciminib by LC-MS/MS method in human plasma: Validation and stability studies. J. Appl. Pharm. Sci. 16(01)164–170 https://doi.org/10.7324/JAPS.2024.163326
Prathyusha, K., Chandrashekara Rao, B. & Chamakuri, K. Method development and validation of LC-ESIMS/MS approach for the quantification of Asciminib in K2EDTA plasma. Rasayan J. Chem. 17, 1500–1508. https://doi.org/10.31788/RJC.2024.1748891 (2024).
ICH harmonised tripartite guideline validation of analytical procedures. text. Methodol. Q2(R1), 1–17 (2005).
Bhupatiraju, R. V., Srinivasa Kumar, B., Tangeti, V. S., Rekha, K. & Sayed, F. LC and LC-MS/MS studies for identification and characterisation of related substances and degradation products of Abrocitinib. Toxicol. Int. 31, 321–334. https://doi.org/10.18311/ti/2024/v31i2/36370 (2024).
Rasheed Babu, S. K., Rama Devi, D., Basavaiah, K. & Rao, B. M. Isolation, LC–MS/MS, NMR characterization, in silico toxicity, and ADME evaluation of stress-degradation products of Sunitinib with optimized stability-indicating HPLC method for quantification of Sunitinib and its impurities. Sep. Sci. Plus 8, e70001. https://doi.org/10.1002/sscp.70001 (2025).
Acknowledgements
The authors express their sincere gratitude to the Department of Inorganic and Analytical chemistry, Andhra University, Visakhapatnam, Andhra Pradesh, India.
Author information
Authors and Affiliations
Contributions
RBS: Conceptualization, data curation, analysis, results curation, Supervision, Writing draft, editing draft. SKRP, MG, DRD, KB, and BMR: Conceptualization, data curation, analysis.All authors approved the manuscript for publication.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Shaik, R.B., Padala, S.K.R., Gupta, M. et al. Structural and In silico safety evaluation of asciminib degradation products with a validated stability indicating HPLC method for genotoxic impurity determination. Sci Rep (2026). https://doi.org/10.1038/s41598-026-44693-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-44693-0
